Graft-versus-host disease (GVHD) is a potentially serious complication that can occur after a stem cell or bone marrow transplant, where the transplanted immune cells attack the recipient's tissues and organs. It commonly affects the skin, gastrointestinal tract, and liver, leading to symptoms such as rash, diarrhea, and liver dysfunction. GVHD can range from mild to life-threatening and requires prompt medical intervention, including immunosuppressive therapy, to manage symptoms and prevent further tissue damage.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...